SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Smigal C,Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 10630.
  • 2
    Mendelsohn J,Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 36985.
  • 3
    Hirsch FR,Varella-Garcia M,Bunn PA,Jr,Di Maria MV,Veve R,Bremmes RM,Barón AE,Zeng C,Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798807.
  • 4
    Jorissen RN,Walker F,Pouliot N,Garrett TP,Ward CW,Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284: 3153.
  • 5
    Fukuoka M,Yano S,Giaccone G,Tamura T,Nakagawa K,Douillard JY,Nishiwaki Y,Vansteenkiste J,Kudoh S,Rischin D,Eek R,Horai T, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 223746.
  • 6
    Kris MG,Natale RB,Herbst RS,Lynch TJ,Jr,Prager D,Belani CP,Schiller JH,Kelly K,Spiridonidis H,Sandler A,Albain KS,Cella D, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 214958.
  • 7
    Kakiuchi S,Daigo Y,Ishikawa N,Furukawa C,Tsunoda T,Yano S,Nakagawa K,Tsuruo T,Kohno N,Fukuoka M,Sone S,Nakamura Y. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13: 302943.
  • 8
    Thatcher N,Chang A,Parikh P,Rodrigues Pereira J,Ciuleanu T,von Pawel J,Thongprasert S,Tan EH,Pemberton K,Archer V,Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 152737.
  • 9
    Shepherd FA,Rodrigues Pereira J,Ciuleanu T,Tan EH,Hirsh V,Thongprasert S,Campos D,Maoleekoonpiroj S,Smylie M,Martins R,van Kooten M,Dediu M, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 12332.
  • 10
    Ando M,Okamoto I,Yamamoto N,Takeda K,Tamura K,Seto T,Ariyoshi Y,Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24: 254956.
  • 11
    Lynch TJ,Bell DW,Sordella R,Gurubhagavatula S,Okimoto RA,Brannigan BW,Harris PL,Haserlat SM,Supko JG,Haluska FG,Louis DN,Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 212939.
  • 12
    Paez JG,Jänne PA,Lee JC,Tracy S,Greulich H,Gabriel S,Herman P,Kaye FJ,Lindeman N,Boggon TJ,Naoki K,Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497500.
  • 13
    Mitsudomi T,Kosaka T,Endoh H,Horio Y,Hida T,Mori S,Hatooka S,Shinoda M,Takahashi T,Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 251320.
  • 14
    Ichihara S,Toyooka S,Fujiwara Y,Hotta K,Shigematsu H,Tokumo M,Soh J,Asano H,Ichimura K,Aoe K,Aoe M,Kiura K, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 2007; 120: 123947.
  • 15
    Satouchi M,Negoro S,Funada Y,Urata Y,Shimada T,Yoshimura S,Kotani Y,Sakuma T,Watanabe H,Adachi S,Takada Y,Yatabe Y, et al. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer 2007; 96: 11916.
  • 16
    Kohno N,Inoue Y,Hamada H,Fujioka S,Fujino S,Yokoyama A,Hiwada K,Ueda N,Akiyama M. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer 1994; 8( Suppl.): 813.
  • 17
    Stahel RA,Gilks WR,Lehmann HP,Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer 1994; 8: 626.
  • 18
    Hirasawa Y,Kohno N,Yokoyama A,Inoue Y,Abe M,Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol 1997; 17: 5017.
  • 19
    Kohno N,Kyoizumi S,Awaya Y,Fukuhara H,Yamakido M,Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 6873.
  • 20
    Kohno N,Awaya Y,Oyama T,Yamakido M,Akiyama M,Inoue Y,Yokoyama A,Hamada H,Fujioka S,Hiwada K. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148: 63742.
  • 21
    Inata J,Hattori N,Yokoyama A,Ohshimo S,Doi M,Ishikawa N,Hamada H,Kohno N. Circulating KL-6/MUC1 mucin carrying sialyl Lewis(a) oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma. Int J Cancer 2007; 120: 26439.
  • 22
    Kohno N,Akiyama M,Kyoizumi S,Hakoda M,Kobuke K,Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies. KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18: 20316.
  • 23
    Aoki R,Tanaka S,Haruma K,Yoshihara M,Sumii K,Kajiyama G,Shimamoto F,Kohno N. MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma. Dis Colon Rectum 1998; 41: 126272.
  • 24
    Nagata S,Tanaka S,Haruma K,Kitadai Y,Yoshihara M,Shimamoto F,Kohno N,Chayama K. MUC1 and cathepsin D expression in early colorectal carcinoma showing V type pit pattern. Int J Oncol 2001; 19: 66572.
  • 25
    Kurosaki M,Izumi N,Onuki Y,Nishimura Y,Ueda K,Tsuchiya K,Nakanishi H,Kitamura T,Asahina Y,Uchihara M,Miyake S. Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Hepatol Res 2005; 33: 2507.
  • 26
    Hiraga Y,Tanaka S,Haruma K,Yoshihara M,Sumii K,Kajiyama G,Shimamoto F,Kohno N. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998; 55: 30719.
  • 27
    Kimura T,Tanaka S,Haruma K,Sumii K,Kajiyama G,Shimamoto F,Kohno N. Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol 2000; 16: 5564.
  • 28
    Yamasaki H,Ikeda S,Okajima M,Miura Y,Asahara T,Kohno N,Shimamoto F. Expression and localization of MUC1. MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors. Int J Oncol 2004; 24: 10713.
  • 29
    Ogawa Y,Ishikawa T,Ikeda K,Nakata B,Sawada T,Ogisawa K,Kato Y,Hirakawa K. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res 2000; 6: 406972.
  • 30
    Hollingsworth MA,Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4: 4560.
  • 31
    Schroeder JA,Thompson MC,Gardner MM,Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276: 1305764.
  • 32
    Pochampalli MR,el Bejjani RM,Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007; 26: 1693701.
  • 33
    Ishikawa N,Daigo Y,Takano A,Taniwaki M,Kato T,Hayama S,Murakami H,Takeshima Y,Inai K,Nishimura H,Tsuchiya E,Kohno N, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 917684.
  • 34
    Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom AT,Christian MC,Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516.
  • 35
    Ohshimo S,Yokoyama A,Hattori N,Ishikawa N,Hirasawa Y,Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun 2005; 338: 184552.
  • 36
    Nagai Y,Miyazawa H,Huqun,Tanaka T,Udagawa K,Kato M,Fukuyama S,Yokote A,Kobayashi K,Kanazawa M,Hagiwara K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 727682.
  • 37
    Tanaka T,Nagai Y,Miyazawa H,Koyama N,Matsuoka S,Sutani A,Huqun,Udagawa K,Murayama Y,Nagata M,Shimizu Y,Ikebuchi K, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007; 98: 24652.
  • 38
    Pujol JL,Molinier O,Ebert W,Daurès JP,Barlesi F,Buccheri G,Paesmans M,Quoix E,Moro-Sibilot D,Szturmowicz M,Bréchot JM,Muley T, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90: 2097105.
  • 39
    Kimura H,Kasahara K,Kawaishi M,Kunitoh H,Tamura T,Holloway B,Nishio K. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006; 12: 391521.
  • 40
    Taguchi F,Solomon B,Gregorc V,Roder H,Gray R,Kasahara K,Nishio M,Brahmer J,Spreafico A,Ludovini V,Massion PP,Dziadziuszko R, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007; 99: 83846.
  • 41
    Hirasawa Y,Kohno N,Yokoyama A,Kondo K,Hiwada K,Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161: 58994.
  • 42
    Ohnishi H,Yokoyama A,Yasuhara Y,Watanabe A,Naka T,Hamada H,Abe M,Nishimura K,Higaki J,Ikezoe J,Kohno N. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003; 58: 8725.
  • 43
    Tsutsumida H,Swanson BJ,Singh PK,Caffrey TC,Kitajima S,Goto M,Yonezawa S,Hollingsworth MA. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res 2006; 12: 297687.
  • 44
    Ohgami A,Tsuda T,Osaki T,Mitsudomi T,Morimoto Y,Higashi T,Yasumoto K. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg 1999; 67: 81014.
  • 45
    Tsutsumida H,Goto M,Kitajima S,Kubota I,Hirotsu Y,Yonezawa S. Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 2004; 44: 14755.
  • 46
    Ren J,Agata N,Chen D,Li Y,Yu WH,Huang L,Raina D,Chen W,Kharbanda S,Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004; 5: 1078.
  • 47
    Witta SE,Gemmill RM,Hirsch FR,Coldren CD,Hedman K,Ravdel L,Helfrich B,Dziadziuszko R,Chan DC,Sugita M,Chan Z,Baron A, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66: 94450.
  • 48
    Coldren CD,Helfrich BA,Witta SE,Sugita M,Lapadat R,Zeng C,Barón A,Franklin WA,Hirsch FR,Geraci MW,Bunn PA,Jr. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006; 4: 5218.
  • 49
    Kondo K,Kohno N,Yokoyama A,Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res 1998; 58: 201419.
  • 50
    Doi M,Yokoyama A,Kondo K,Ohnishi H,Ishikawa N,Hattori N,Kohno N. Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping. Cancer Sci 2006; 97: 4209.